Depressive Disorder News and Research

RSS

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

Does a psychedelic need an awake brain to have lasting effects? This mouse study offers a clue

A single dose of psilocybin produced a lasting increase in sociability for at least two weeks in Cntnap2-knockout mice with social deficits, while it did not enhance sociability overall in mice with normal social behavior. The effect required 5-HT2A receptor activation and persisted when psilocybin was administered under light anesthesia, suggesting that wakefulness during the drug’s acute effects was not necessary for this behavioral response.

30 Aug 2026

Probiotics for mental health? A new review finds promising signals and major gaps

This narrative review examines how psychobiotics may influence anxiety, depression, bipolar disorder, and schizophrenia through gut-brain pathways involving neurotransmitters, inflammation, immune regulation, gut barrier function, and stress signaling. Specific Lactobacillus and Bifidobacterium strains showed encouraging effects, but wide differences in strains, doses, populations, and study designs currently limit clinical translation.

28 Aug 2026

Neurogenesis stalls in the brains of adults with major depressive disorder, study shows

Most of our brain's 100 billion neurons are created before we're born, but the trickle of neurons created in the adult brain hippocampus could be instrumental in preventing depression, suggest findings from a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons.

21 Aug 2026

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

A single 25-mg dose of psilocybin with psychological support was feasible to deliver within an NHS setting and produced large preliminary reductions in depressive symptoms among adults with treatment-resistant depression. The Phase 2 feasibility trial also found the treatment was generally well tolerated, although functional unblinding and expectancy effects mean larger, longer efficacy studies are needed.

10 Aug 2026

Inflammatory bowel disease linked to elevated risk of psychiatric disorders

Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade after, according to a nationwide study to be published in Clinical Gastroenterology and Hepatology.

5 Aug 2026

Dementia addiction and psychiatric disorders show distinct patterns of accelerated brain aging

People with dementia, mild cognitive impairment, alcohol addiction, or psychiatric disorders such as schizophrenia show increased brain aging, each in specific patterns within the brain, according to a study published July 21st in the open access journal PLOS Medicine by Shile Qi from the Nanjing University of Aeronautics and Astronautics, China, and colleagues.

21 Jul 2026

GLP-1 receptor activation linked to lower depression and bipolar disorder odds

Genetic analyses linked BMI-related GLP-1 receptor activation to better mental well-being and lower odds of major depressive disorder and bipolar disorder. The findings do not prove that GLP-1 receptor agonist drugs treat psychiatric conditions, and randomized clinical trials are still needed.

15 Jul 2026

New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

A Molecular Psychiatry review shows that depression in Alzheimer’s and Parkinson’s disease may reflect disease-specific molecular, neurotransmitter, inflammatory, and circuit-level disruptions rather than standard depression biology alone. It argues that broad antidepressants often show limited efficacy in these patients and that future trials should use biomarkers, neuroimaging, and symptom profiling to guide targeted treatments.

7 Jul 2026

Psychiatry may be moving closer to precision medicine

For decades, treating depression has largely involved a difficult form of medical guesswork: prescribing one antidepressant after another in hopes that one will eventually help.

6 Jul 2026

Review assesses the efficacy of creatine as an add-on therapy for depression

Walk into any gym supplement aisle and creatine is there, sold by the tub to people chasing bigger muscles. It is one of the most studied compounds in sports science.

30 Jun 2026

Functional brain imaging can help guide accelerated TMS for depression

Mass General Brigham study suggests that functional brain imaging can help guide accelerated transcranial magnetic stimulation for depression.

24 Jun 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Depression shapes how children pay attention to emotional faces

A smile. A frown. The faces a child pays closer attention to might offer invaluable insight into their mental health.

16 Jun 2026

New USC clinical trial explores psilocybin for mental health

Researchers at the Keck School of Medicine of USC, the Brain and Creativity Institute at the USC Dornsife College of Letters, Arts and Sciences, and the USC Norris Comprehensive Cancer Center have launched the University of Southern California's first study of psychedelic therapy.

16 Jun 2026

Gut bacteria may help explain why fatigue appears before illness

A small study of healthy Japanese adults found that fatigue was associated with distinct gut microbiome, microbial gene, and fecal metabolite patterns. The findings suggest fatigue may track with altered microbial energy metabolism and oxidative stress-related functional potential, but larger longitudinal studies are needed to test causality and clinical value.

16 Jun 2026

Scientists introduce a precise framework to study screen-saturated childhoods

Children are growing up inside screens. A new peer-reviewed Thought Leaders Invited Review in Brain Health argues that neuroscience has been missing the word for what those screens are touching.

3 Jun 2026

Ghrelin rises in depression despite obesity’s usual appetite-hormone suppression

Researchers found that both acylated and deacylated ghrelin were elevated in unmedicated adults with major depressive disorder and obesity compared with non-depressed adults with obesity. The cross-sectional findings suggest ghrelin-system dysregulation may be linked to depression in obesity, but larger longitudinal studies are needed to test whether ghrelin is a reliable biomarker.

27 May 2026

Mental disorders surpass other conditions as leading global cause of disability

Nearly 1.2 billion people worldwide are living with a mental disorder, nearly double the number recorded in 1990.

22 May 2026

Massive global analysis examines cognitive development in children of affected parents

A new study led by Murdoch University has found that children of parents with severe mental illness are more likely to experience cognitive difficulties.

19 May 2026

Depressive Disorder News and Research

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

Does a psychedelic need an awake brain to have lasting effects? This mouse study offers a clue

Probiotics for mental health? A new review finds promising signals and major gaps

Neurogenesis stalls in the brains of adults with major depressive disorder, study shows

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

Inflammatory bowel disease linked to elevated risk of psychiatric disorders

Dementia addiction and psychiatric disorders show distinct patterns of accelerated brain aging

GLP-1 receptor activation linked to lower depression and bipolar disorder odds

New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

Psychiatry may be moving closer to precision medicine

Review assesses the efficacy of creatine as an add-on therapy for depression

Functional brain imaging can help guide accelerated TMS for depression

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

Depression shapes how children pay attention to emotional faces

New USC clinical trial explores psilocybin for mental health

Gut bacteria may help explain why fatigue appears before illness

Scientists introduce a precise framework to study screen-saturated childhoods

Ghrelin rises in depression despite obesity’s usual appetite-hormone suppression

Mental disorders surpass other conditions as leading global cause of disability

Massive global analysis examines cognitive development in children of affected parents

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News